Pigment epithelium-derived factor inhibits advanced glycation end products-induced retinal vascular permeability

Biochimie

Volumn 92, Issue 8, 2010, Pages 1040-1051

  Sheikpranbabu, Sardarpasha ^a   Haribalaganesh, Ravinarayanan ^a   Lee, Kyung Jin ^b   Gurunathan, Sangiliyandi ^a  

^a KALASALINGAM UNIVERSITY   (India)

^b Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

AGE BSA; NADPH; PEDF; PI3K Akt; ROS; Vascular permeability; ZO 1

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BOVINE SERUM ALBUMIN; DEXTRAN; FLUORESCENT DYE; PHOSPHATIDYLINOSITOL 3 KINASE; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN KINASE B; PROTEIN P22; PROTEIN ZO1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHODAMINE B ISOTHIOCYANATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETINA; SIGNAL TRANSDUCTION;

ANIMALS; BLOTTING, WESTERN; CAPILLARY PERMEABILITY; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE PROTEINS; GLYCOSYLATION END PRODUCTS, ADVANCED; NERVE GROWTH FACTORS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; REACTIVE OXYGEN SPECIES; RETINAL VESSELS; SERPINS; SWINE;

BOVINAE; SUS;

EID: 77954660494     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.05.004     Document Type: Article

References (64)

1. Yamagishi S., Nakamura K., Matsui T., Inagaki Y., Takenaka K., Jinnouchi Y., Yoshida Y., Matasuura T., Narama I., Motomiya Y., Takeuchi M., Inoue H., Yoshimura A., Bacula R., Imaizumi T. Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor (VEGF) expression. J. Biol. Chem. 2006, 281:20213-20220.
2. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 1998, 318:1315-1320.
3. Dyer D., Blackledge J., Thorpe S., Baynes J. Formation of pentosidine during nonenzymatic browning of proteins by glucose. J. Biol. Chem. 1991, 266:11654-11660.
4. Makita Z., Radoff S., Rayfield E.J., Yang Z., Skolnik E., Friedmann E.A., Cerami A., Vlassara H. Advanced glycosylation in patients with diabetic nephropathy. N. Engl. J. Med. 1991, 325:836-842.
5. Vlassara H., Fuh H., Makita Z., Krungkrai S., Cerami A., Bucala R. Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:12043-12047.
6. Yan S.D., Schmidt A.M., Anderson M., Zhang J., Bertt J., Zou Y.S., Pinsky D., Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 1994, 269:9889-9897.
7. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., Schmidt A.M. Activation of the receptor for advanced glycation end products triggers a p21 ras dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 1997, 272:17810-17814.
8. Wautier J.L., Guillausseau P.J. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab. (Paris) 2001, 21:535-542.
9. Stitt A.W., Li Y.M., Gardiner T.A., Bucala R., Archer D.B., Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am. J. Pathol. 1997, 150:523-531.
10. Hammes H.P., Alt A., Niwa T., Bretzel R.G., Brownlee M., Schleicher E. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999, 42:728-736.
11. Tanaka N., Yonekura H., Yamagishi S., Fujimori H., Yamamoto Y., Yamamoto H. The receptor for advanced glycation end products is induced by glycation products themselves and tumor necrosis factor-α through nuclear factor-κB and by 17β-estradiol through sp-1 in human vascular endothelial cells. J. Biol. Chem. 2000, 275:25781-25790.
12. Stitt A.W., Bhaduri T., McMullen C.B., Gardiner T.A., Archer D.B. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol. Cell Biol. Res. Commun. 2000, 3:380-388.
13. Antonetti D.A., Barber A.J., Khin S., Lieth E., Tarbell J.M., Gardner T.W. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 1998, 47:1953-1959. Penn State Retina Research Group.
14. Aiello L.P., Gardner T.W., King G.L., Blankenship G., Cavallerano J.D., Ferris F.L., Klein R. Diabetic retinopathy: technical review. Diabetes Care 1998, 21:143-156.
15. Erickson K.K., Sundstrom J.M., Antonetti D.A. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 2007, 10:103-117.
16. Dawson D.W., Volpert O.V., Gillis P., Crawford S.E., Xu H., Benedict W., Bouck N.P. Pigment epithelium derived factor: a potent inhibitor of angiogenesis. Science 1999, 285:245-248.
17. Tombran-Tink J., Barnstable C.J. Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor. Trends Mol. Med. 2003, 9:244-250.
18. Elayappan B., Ravinarayannan H., Sardarpasha S.P.B., Lee K., Gurunathan S. PEDF-inhibits VEGF and EPO-induced angiogenesis in retinal endothelial cells through interruption of PI3K/Akt phosphorylation. Angiogenesis 2009, 10.1007/s10456-009-9153-5.
19. Stellmach V., Crawford S.E., Zhou W., Bouck N. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:2593-2597.
20. Duh E.J., Yang H.S., Suzuma Y.I., Miyagi M., Youngman E., Mori K., Katai M., Yan L., Suzuma K., West K., Davarya S., Tong P., Gehlbach P., Pearlman J., Crabb J.W., Aiello L.P., Campochiaro P.A., Zack D.J. Pigment epithelium derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest. Ophthalmol. Vis. Sci. 2002, 43:821-829.
21. Spranger J., Osterhoff M., Reimann M., Mohlig M., Ristow M., Francis M.K., Cristofalo V., Hammes H.P., Smith G., Boulton M., Pfeiffer F.H. Loss of anti-angiogenic pigment epithelium derived factor in patients with angiogenic eye disease. Diabetes 2002, 50:2641-2645.
22. Ren J.G., Jie C., Talbot C. How PEDF prevents angiogenesis: a hypothesized pathway. Med. Hypotheses 2005, 64:74-78.
23. Toker A., Cantly L.C. Signaling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997, 387:673-676.
24. Jiang B.H., Zheng J.Z., Aoki M., Vogt P.K. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:1749-1753.
25. Babior B.M. NADPH oxidase: an update. Blood 1999, 93:1464-1476.
26. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 2007, 87:245-313.
27. Vignais P.V. The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell. Mol. Life Sci. 2002, 59:1428-1459.
28. Bokoch G.M., Knaus U.G. NADPH oxidases: not just for leukocytes any more!. Trends Biochem. Sci. 2003, 28:502-508.
29. Yoshida T., Yamagishi S., Nakamura K., Matsui T., Imaizumi T., Takeuchi M., Ueno T., Sata M. Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end-product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. FEBS Lett. 2006, 580:2788-2796.
30. Sheikpranbabu S., Haribalaganesh R., Banumathi E., Sirishkumar N., Lee K.J., Gurunathan S. Pigment epithelium-derived factor inhibits advanced glycation end-product-induced angiogenesis and stimulates apoptosis in retinal endothelial cells. Life Sci. 2009, 85:719-731.
31. Antonetti D.A., Wolpert E.B., DeMaio L., Harhaj N.S., Scaduto R.C. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J. Neurochem. 2002, 80:667-677.
32. Wang Y., Fei D., Vanderlaan M., Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004, 7:335-345.
33. Lee K.S., Kim S.R., Park S.J., Lee H.K., Park H.S., Min K.H., Jin S.M., Lee Y.C. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) reduces vascular endothelial growth factor expression in allergen induced airway inflammation. Mol. Pharmacol. 2006, 69:1829-1839.
34. Banumathi E., Sheikpranbabu S., Haribalaganesh R., Sangiliyandi G. PEDF prevents reactive oxygen species generation and retinal endothelial cell damage at high glucose levels. Exp. Eye Res. 2010, 90:89-96.
35. Kwak Y.G., Song C.H., Yi H.K., Hwang P.H., Kim J.S., Lee K.S., Lee Y.C. Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J. Clin. Invest. 2003, 111:1083-1092.
36. Liu H., Ren J.G., Cooper W.L., Hawkins C.E., Cowan M.R., Tong P.Y. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:6605-6610.
37. Tombran-Tink J., Barnstable C.J. PEDF: a multifaceted neurotrophic factor. Nat. Rev. Neurosci. 2003, 4:628-636.
38. Yamagishi S., Yonekura H., Yamamoto Y., Katsuno K., Sato F., Mita I., Ooka H., Satozawa N., Kawakami T., Nomura M., Yamamoto H. Advanced glycation end products-driven angiogenesis in vitro. J. Biol. Chem. 1997, 272:8723-8730.
39. Stitt A.W., McGoldrick C., Rice-McCaldin A., McCance D.R., Glenn J.V., Hsu D.K., Liu F.T., Throrpe S.R., Gardiner T.A. Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. Diabetes 2005, 53:785-794.
40. Hori O., Brett J., Slattery T., Cao R., Zhang J., Chen J.X., Nagashima M., Lundh E.R., Vijay S., Nitecki D., Morser J., Stern D., Schmidt A.M. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. J. Biol. Chem. 1995, 270:25752-25761.
41. Sakata N., Meng J., Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J. Atheroscler. Thromb. 2000, 7:169-176.
42. Yamagishi S., Takeuchi M., Inagaki Y., Nakamura K., Yoshida T., Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int. J. Clin. Pharmacol. Res. 2003, 23:129-134.
43. Triens C., Peraldi S.G., Murdaca J., Obberghen E.V. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J. Biol. Chem. 2001, 43836-43841.
44. Goldin A., Beckman J.A., Schmidt A.M., Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605.
45. Tezuka M., Koyama N., Morisaki N., Saito Y., Yoshida S., Araki N., Horiuchi S. Angiogenic effects of advanced glycation end products of the maillard reaction on cultured human umbilical cord vein endothelial cells. Biochem. Biophys. Res. Commun. 1993, 193:674-680.
46. Cai J., Jiang W.G., Grant M.B., Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor-1. J. Biol. Chem. 2006, 281:3604-3613.
47. Yamagishi S., Matsui T., Inagaki Y., Nakamura K., Takeuchi M., Inoue H., Yoshida Y., Imaizumi T. Pigment epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats. Ophthalmic Res. 2007, 39:92-97.
48. Alessi D.R., Caudwell F.B., Andjelkovic M., Hemmings B.A., Cohen P. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett. 1996, 399:333-338.
49. Testa J.R., Bellacosa A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10983-10985.
50. Paolisso G., Giuglianoc D. Oxidative stress and insulin action: is there a relationship?. Diabetologia 1996, 39:357-363.
51. Anderson M.M., Requena J.R., Crowley J.R., Thorpe S.R., Heinecke J.W. The myeloperoxidase system of human phagocytes generates N(epsilon)- (carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J. Clin. Invest. 1999, 104:103-113.
52. Anderson M.M., Heinecke J.W. Production of N(epsilon)-(carboxymethyl) lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation. Diabetes 2003, 52:2137-2143.
53. Huebschmann A.G., Vlassara H., Regensteiner J.G., Reusch J.E.B. Diabetes and advanced glycoxidation end products. Diabetes Care 2006, 29:1420-1432.
54. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 2001, 108:949-955.
55. Basta G., Lazzerini G., Massaro M., Simoncini T., Tanganelli P., Fu C., Kislinger T., Stern D.M., Schmidt A.M., De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002, 105:816-822.
56. Min C., Kang E., Yu S., Shinn S., Kim Y. Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells. Diabetes Res. Clin. Pract. 1999, 46:197-202.
57. Alikhani M., MacLellan C.M., Raptis M., Vora S., Trackman P.C., Graves D.T. Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor. Am. J. Physiol. Cell Physiol. 2007, 292:C850-C856.
58. Inagaki Y., Yamagishi S., Okamoto T., Takeuchi M., Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemo attractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003, 46:284-287.
59. Zhu Q.S., Xia L., Mills G.B., Lowell C.A., Touw I.P., Corey S.J. G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth. Blood 2006, 107:1847-1856.
60. Harhaj N.S., Antonetti D.A. Regulation of tight junctions and loss of barrier function in pathophysiology. Int. J. Biochem. Cell Biol. 2004, 36:1206-1237.
61. Stevenson B.R., Siliciano J.D., Mooseker M.S., Goodenough D.A. Identification of ZO-1, a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J. Cell Biol. 1986, 103:755-766.
62. Tsukita S., Furuse M., Itoh M. Multifunctional strands in tight junctions. Nat. Rev. Mol. Cell Biol. 2001, 2:286-293.
63. Antonetti D.A., Barber A.J., Hollinger L.A., Wolpert E.B., Gardner T.W. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden-1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J. Biol. Chem. 1999, 274:23463-23467.
64. Furuse M., Itoh M., Hirase T., Nagafuchi A., Yonemura S., Tsukita S. Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J. Cell. Biol. 1994, 127:1617-1626.